复方鲜竹沥液联合噻托溴铵粉雾剂治疗慢性阻塞性肺疾病急性加重期的临床研究

目的研究复方鲜竹沥液联合噻托溴铵粉雾剂治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法选取2018年9月—2019年9月在安阳市第六人民医院治疗的100例慢性阻塞性肺疾病急性加重期患者,将所有患者随机分为对照组和治疗组,每组各50例。对照组吸入噻托溴铵粉雾剂,1粒/次,1次/d。治疗组在对照组基础上口服复方鲜竹沥液,20 mL/次,3次/d。两组持续治疗3个月。观察两组的临床疗效,比较血气指标、肺功能指标、血清炎性因子水平。结果治疗后,治疗组总有效率94.00%显著高于对照组82.00%(P<0.05)。治疗后,两组二氧化碳分压(pCO2)显著降低,血氧分压(pO2)显著升高(P<0.05),且治疗组血气指标改善程度较大(P<0.05)。治疗后,两组第一秒用力呼气容积(FEV1)占预计值百分比(FEV1%)、每分钟最大通气量(MVV)显著升高,残气量/肺总量(RV/TLC)明显降低(P<0.05);且治疗组肺功能指标改善较多(P<0.05)。治疗后,两组白细胞介素-17(IL-17)、IL-8、肿瘤坏死因子-α(TNF-α)水平显著降低(P<0.05);并且治疗组血清炎性因子水平降低较多(P<0.05)。结论复方鲜竹沥液联合噻托溴铵粉雾剂治疗慢性阻塞性肺疾病急性加重期具有较好的临床疗效,可改善血气指标和肺功能指标,降低血清炎性因子水平,值得在临床上推广应用。

Clinical study on Compound Xianzhuli Liquids combined with Tiotropium Bromide Powder for inhalation in treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective To study the clinical effect of Compound Xianzhuli Liquids combined with Tiotropium Bromide Powder for inhalation in treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods Patients(100 cases)with AECOPD in Anyang People’s Hospital NO.6 from September 2013 to September 2015 were randomly divided into control and treatment groups,and each group had 50 cases.Patients in the control group were inhalation administered with Tiotropium Bromide Powder for inhalation,1 grain/time,once daily.Patients in the treatment group were po administered with Compound Xianzhuli Liquids on the basis of the control group,20 m L/time,three times daily.Patients in two groups were treated for 3 months.After treatment,the clinical efficacies were evaluated,and blood gas indexes,pulmonary function indexes,and the serum levels of inflammatory factors in two groups were compared.Results After treatment,the total effective rate in the treatment group was 94.00%,which was significantly higher than that in the control group(82.00%)(P<0.05).After treatment,the level of pCO2 in the two groups were significantly decreased,but the levels of pO2 in two groups were significantly increased(P<0.05),and the blood gas indexes in the treatment group were better than those in the control group(P<0.05).After treatment,FEV1%and MVV in the two groups were significantly increased,but RV/TLC in the two groups were significantly decreased(P<0.05),and the pulmonary function indexes in the treatment group were better than those in the control group(P<0.05).After treatment,the levels of IL-17,IL-8,and TNF-αin the two groups were significantly decreased(P<0.05),and the the serum levels of inflammatory factors in the treatment group were better than those in the control group(P<0.05).Conclusion Compound Xianzhuli Liquids combined with Tiotropium Bromide Powder for inhalation has clinical curative effect in treatment of AECOPD,can improve blood gas index and lung function index,reduce serum level inflammatory factor,which is worthy of clinical application.